Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
67 hedge funds and large institutions have $22.9M invested in Adaptimmune Therapeutics in 2025 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 19 closing their positions.
633% more call options, than puts
Call options by funds: $22K | Put options by funds: $3K
6% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 16
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.58% less ownership
Funds ownership: 8.1% → 7.52% (-0.58%)
16% less funds holding
Funds holding: 80 → 67 (-13)
58% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 19
66% less capital invested
Capital invested by funds: $67M → $22.9M (-$44.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSC
Two Seas Capital
Rye,
New York
|
+$2.95M |
| 2 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$1.69M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$884K |
| 4 |
Morgan Stanley
New York
|
+$720K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$451K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$6.37M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$2.62M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$888K |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$385K |
| 5 |
Renaissance Technologies
New York
|
-$369K |
ADAP Hedge Fund Activity: Q1 2025 in Review
67 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q1 2025, worth a combined $22.9M — down 66% from $67M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of ADAP and 8 opened new positions — a net loss of 11 holders — while 16 trimmed existing stakes and 17 added.
The largest buyer was Two Seas Capital, adding an estimated $2.95M. The largest seller was Baillie Gifford & Co, exiting entirely with an estimated $6.37M sold.
- 67 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q1 2025, down from 80 in Q4 2024.
- Funds reported $22.9M of Adaptimmune Therapeutics stock for Q1 2025, down 66% quarter-over-quarter.
- 8 funds opened new Adaptimmune Therapeutics positions in Q1 2025 and 19 closed out, a net change of -11 holders.
- The largest Adaptimmune Therapeutics buyer in Q1 2025 was Two Seas Capital, an estimated $2.95M added.
- The largest Adaptimmune Therapeutics seller in Q1 2025 was Baillie Gifford & Co, an estimated $6.37M sold.
Based on aggregated 13F filings for Q1 2025.